EYWN.F bioMérieux S.A

Healthcare Biotechnology Frankfurt Exchange
91.50 EUR
Close of Nov 12, 2026
63.10 112.24
Market cap
EUR 10.8B
P/E
23.5x
P/B
2.50x
ROE
9.7%
Dividend yield
0.99%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is EYWN.F undervalued?

Graham number
Price91.50
Graham value56.70
Premium61.4%

EYWN.F trades 61.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

bioMérieux S.A fundamental analysis

No fundamental analysis for bioMérieux S.A yet.

bioMérieux S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About bioMérieux S.A

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymeras…

Full company profile